Atossa Genetics (NASDAQ:ATOS) Stock Price Crosses Above 200 Day Moving Average - Should You Sell?

Key Points

• Atossa Genetics' stock price has recently surpassed its 200-day moving average of $0.82, trading as high as $1.08 before settling at $1.05.
• The stock received mixed ratings from analysts, with Zacks downgrading it to "strong sell" while Ascendiant Capital Markets issued a "buy" rating, raising the target price to $7.75.
• Institutional investors have increased their stakes in Atossa Genetics, with ownership now at 12.74% among hedge funds and other institutional investors.

Atossa Genetics Inc. (NASDAQ:ATOS - Get Free Report)'s stock price passed above its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $0.82 and traded as high as $1.08. Atossa Genetics shares last traded at $1.05, with a volume of 802,332 shares trading hands.

Wall Street Analyst Weigh In

Several equities research analysts have commented on ATOS shares. Zacks Research downgraded shares of Atossa Genetics from a "hold" rating to a "strong sell" rating in a report on Monday. Ascendiant Capital Markets upped their target price on Atossa Genetics from $7.50 to $7.75 and gave the stock a "buy" rating in a research note on Monday, September 22nd. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Atossa Genetics in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and two have assigned a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of "Hold" and an average price target of $6.25.

Atossa Genetics Trading Up 1.9%

The stock has a 50 day simple moving average of $0.85 and a 200-day simple moving average of $0.82. The firm has a market cap of $135.63 million, a P/E ratio of -4.57 and a beta of 1.11.

Atossa Genetics (NASDAQ:ATOS - Get Free Report) last announced its quarterly earnings data on Tuesday, August 12th. The company reported ($0.07) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.01). As a group, equities analysts forecast that Atossa Genetics Inc. will post -0.22 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Atossa Genetics

A number of institutional investors have recently added to or reduced their stakes in the stock. Hudson Bay Capital Management LP purchased a new stake in Atossa Genetics in the second quarter valued at $26,000. Catalyst Funds Management Pty Ltd purchased a new stake in Atossa Genetics during the 2nd quarter valued at approximately $49,000. Bank of America Corp DE raised its stake in Atossa Genetics by 55.7% during the 2nd quarter. Bank of America Corp DE now owns 99,601 shares of the company's stock valued at $83,000 after acquiring an additional 35,629 shares during the last quarter. Nuveen LLC purchased a new position in shares of Atossa Genetics during the 1st quarter worth approximately $115,000. Finally, Charles Schwab Investment Management Inc. increased its stake in Atossa Genetics by 40.1% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 422,582 shares of the company's stock valued at $284,000 after purchasing an additional 120,934 shares in the last quarter. Hedge funds and other institutional investors own 12.74% of the company's stock.

Atossa Genetics Company Profile

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.